Revolution Medicines (NASDAQ: RVMD) Price Target Jumps to $260 After RASONQUE FDA Approval

• Oppenheimer has increased its price target for Revolution Medicines (NASDAQ: RVMD) to $260.00, signaling strong confidence in the biopharmaceutical company.
• The U.S. Food and Drug Administration (FDA) has approved RASONQUE (daraxonrasib), Revolution Medicines' first broad RAS-targeted medicine for metastatic pancreatic cancer.
• RASONQUE demonstrated a significant 60% reduction in the risk of death in its Phase 3 trial, showcasing strong clinical results.

Revolution Medicines (NASDAQ: RVMD) is a biopharmaceutical company focused on developing new therapies to treat cancer. On August 26, 2026, an analyst from Oppenheimer increased their price target for Revolution Medicines to $260.00. This suggests a positive outlook on the company's future performance.

The analyst's updated target follows major news from Revolution Medicines. Revolution Medicines announced that the U.S. Food and Drug Administration (FDA) has approved its drug, RASONQUE (daraxonrasib). This is the first broad RAS-targeted medicine for metastatic pancreatic cancer, a disease that, as highlighted by WSJ, is fatal for seven out of eight patients within five years.

The approval is based on strong clinical trial results. In its Phase 3 trial, RASONQUE showed a significant 60% reduction in the risk of death when compared to standard chemotherapy. The drug also demonstrated a manageable safety profile and improved the quality of life for patients, according to Revolution Medicines' announcement.

This significant development supports the analyst's optimism. At the time of the announcement, Revolution Medicines was trading at $215.44. The new $260.00 price target represents a potential upside of about 20.68%, as published by StreetInsider. Revolution Medicines currently has a market capitalization of approximately $45.80 billion.